High potency ADCs - from discovery to the clinic

Posted on: 06/11/2017

Antibody–drug conjugates (ADCs) are one of the fastest growing classes of oncology therapeutics.

ADCs are empowered antibodies intended to target therapy for the treatment of people with cancer. They are designed to kill only the cancer cells so that healthy cells are not affected significantly.

The Knowledge Transfer Network is hosting an event, in partnership with MedImmune, to bring together the Antibody Drug Conjugate discovery, development and manufacturing community in human health in the UK. The event will take place on Monday 11th December 2017 at MedImmune, Great Abington, Cambridge CB21 6GH.

Discussions will cover the latest innovative technologies in target identification, process development and manufacturing of all component parts of ADCs, novel toxins and linkers in development, and successes of ADCs already in clinical development. Learn about UK capabilities and future opportunities for this sector, identified in the MMIP Technology and Innovation workstream, of funding opportunities to support innovative companies through Innovate UK, including the Industrial Strategy Challenge Fund.

There are less than 20 places left for this event which is also open to the wider sector. Thanks to the generosity of our hosts, and supporters including Glythera and ADC Biotechnology, KTN is able to deliver this meeting as a free event for the community.

More details at our events page.

Share this article


Connect with Innovate UK Business Connect

Join Innovate UK Business Connect's mailing list to receive updates on funding opportunities, events and to access Innovate UK Business Connect's deep expertise. Please check your email to confirm your subscription and select your area(s) of interest.